Medical Oncology

, Volume 26, Supplement 1, pp 13–17 | Cite as

The application of high-dose interleukin-2 for metastatic renal cell carcinoma

Original Paper


Renal cell carcinoma (RCC) evokes an immune response, which has occasionally resulted in spontaneous and dramatic remissions [1, 2, 3]. In an attempt to reproduce or accentuate this response, various immunotherapeutic strategies have been studied. The most consistent anti-tumor activity has been reported with interferon alfa (IFN-α) and interleukin 2 (IL-2). In recent years, randomized trials have suggested that high-dose intravenous bolus IL-2 is superior in terms of response rate and possibly response quality to regimens that involve either low-dose IL-2 and IFN-α, intermediate- or low-dose IL-2 alone, or low-dose IFN-α alone. As this list of effective therapies for RCC grows, improvements in patient selection will be necessary to ensure that the only therapy capable of producing durable remissions will remain available to the patients who should receive it [4, 5, 6, 7].


Immunotherapy Renal cancer Interleukin-2 Carbonic anhydrase IX 



This work was supported in part by the DF/HCC Renal Cancer SPORE: P50 CA101942-01.


  1. 1.
    Gleave ME, Ehilali M, Fradet Y, et al. Canadian Urologic Oncology Group: interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med. 1998;338:1265–71. doi: 10.1056/NEJM199804303381804.PubMedCrossRefGoogle Scholar
  2. 2.
    Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol. 1989;63:128–31. doi: 10.1111/j.1464-410X.1989.tb05147.x.PubMedCrossRefGoogle Scholar
  3. 3.
    Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol. 1992;148:1247–8.PubMedGoogle Scholar
  4. 4.
    Escudier B, Eisen T, Stadler W, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34. doi: 10.1056/NEJMoa060655.PubMedCrossRefGoogle Scholar
  5. 5.
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24. doi: 10.1056/NEJMoa065044.PubMedCrossRefGoogle Scholar
  6. 6.
    Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med. 2007;356(22):2271–81. doi: 10.1056/NEJMoa066838.PubMedCrossRefGoogle Scholar
  7. 7.
    Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind Phase III trial. Lancet. 2007;370(9605):2103–11. doi: 10.1016/S0140-6736(07)61904-7.PubMedCrossRefGoogle Scholar
  8. 8.
    Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–96.PubMedGoogle Scholar
  9. 9.
    Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant Interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6:S55–7.PubMedGoogle Scholar
  10. 10.
    Rosenberg SA, Yang JC, White DE, Steinberg SM, et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2 Identification of the antigens mediating response. Ann Surg. 1998;228:307–19. doi: 10.1097/00000658-199809000-00004.PubMedCrossRefGoogle Scholar
  11. 11.
    Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d’Immunotherapie. N Engl J Med. 1998;338:1272–8. doi: 10.1056/NEJM199804303381805.PubMedCrossRefGoogle Scholar
  12. 12.
    Yang JC, Sherry RM, Stienberg SM, et al. A three-arm randomized comparison of high and low dose intravenous and subcutaneous interleukin-2 in the treatment of metastatic renal cancer. J Clin Oncol. 2003;21:3127–32. doi: 10.1200/JCO.2003.02.122.PubMedCrossRefGoogle Scholar
  13. 13.
    Sleijfer DT, Janssen RA, Buter J, et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol. 1992;10:1119–23.PubMedGoogle Scholar
  14. 14.
    McDermott DF, Regan MM, Clark JI, et al. A randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(1):133–41. doi: 10.1200/JCO.2005.03.206.PubMedCrossRefGoogle Scholar
  15. 15.
    Negrier S, Perol D, Ravaud C, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results from a randomized controlled trial. Cancer. 2007;110(11):2468–77. doi: 10.1002/cncr.23056.PubMedCrossRefGoogle Scholar
  16. 16.
    Besana C, Borri A, Bucci E, et al. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous α-interferon. Eur J Cancer. 1994;9:1292–8. doi: 10.1016/0959-8049(94)90176-7.CrossRefGoogle Scholar
  17. 17.
    Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989;7:1863–74.PubMedGoogle Scholar
  18. 18.
    Figlin R, Gitlitz B, Franklin J, et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am. 1997;3:S92–7.PubMedGoogle Scholar
  19. 19.
    Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;98(12):2566–75. doi: 10.1002/cncr.11851.PubMedCrossRefGoogle Scholar
  20. 20.
    Royal RE, Steinberg SM, Krouse RS, et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am. 1996;2:91–8.PubMedGoogle Scholar
  21. 21.
    Atkins MB, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med. 1988;318:1557–63.PubMedGoogle Scholar
  22. 22.
    Fumagalli LA, Vinke J, Hoff W, et al. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J. Immunother. 2003;26:394–402. doi: 10.1097/00002371-200309000-00002.PubMedCrossRefGoogle Scholar
  23. 23.
    West WH, Tauer KW, Yanelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987;316:898–905.PubMedGoogle Scholar
  24. 24.
    Janik JE, Sznol M, Urba WJ, et al. Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors. Cancer. 1993;72:2656–9. doi:10.1002/1097-0142(19931101)72:9<2656::AID-CNCR2820720922>3.0.CO;2-A.PubMedCrossRefGoogle Scholar
  25. 25.
    Negrier S, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol. 2000;18:4009–15.PubMedGoogle Scholar
  26. 26.
    Bui MHT, Seligson D, Han K, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802–11.PubMedGoogle Scholar
  27. 27.
    Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin Cancer Res. 2005;11(10):3714–21. doi: 10.1158/1078-0432.CCR-04-2019.PubMedCrossRefGoogle Scholar
  28. 28.
    Pantuck AJ, Fang Z, Liu X, et al. Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2005;4:535.Google Scholar
  29. 29.
    Jaeger E, Waldman R, Roydasgupta T, et al. Array-based comparative genomic hybridization identifies chromosomal imbalances between interleukin-2 complete and non-responders. J Clin Oncol. 2008;26 (May 20 suppl; abstr 5043).Google Scholar
  30. 30.
    Schwarzberg T, Regan MM, Liu V, et al. Retrospective analysis of interleukin-2 therapy in patients with metastatic renal cell carcinoma who had received prior antiangiogenic therapy. J Clin Oncol. 2008 (May 20 suppl; abstr 5044).Google Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  1. 1.Biologic Therapy ProgramBeth Israel Deaconess Medical CenterBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA
  3. 3.Clinical Research Sub-CommitteeDana-Farber/Harvard Cancer Center Renal Cancer ProgramBostonUSA

Personalised recommendations